Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 7/20 | 0.55 |
| ▸ | CNR1 | P21554 | 3/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27626389 | 0.80 | HTR1A (0.68) | MEN1POLBKMT2ANAMPTNPSR1 | |
| SCHEMBL5733628 | 0.80 | MAPT (0.71) | MEN1POLBKMT2ANAMPTCNR1 | |
| SCHEMBL8304884 | 0.78 | CYP3A4 (0.63) | CYP3A4CYP2D6MEN1KMT2AKDM4E | |
| SCHEMBL13595586 | 0.73 | KDM4E (0.52) | MEN1POLBKMT2AKDM4EGAA | |
| SCHEMBL8300077 | 0.73 | CYP3A4 (0.56) | CYP3A4CYP2D6KDM4EGAAHSD17B10 | |
| SCHEMBL15329158 | 0.73 | CYP3A4 (1.00) | CYP3A4CYP2D6NAMPTKDM4EGAA | |
| SCHEMBL10923255 | 0.73 | KMT2A (0.97) | MEN1POLBKMT2ACNR1NPSR1 | |
| SCHEMBL7670700 | 0.72 | POLB (0.69) | CYP3A4CYP2D6POLBKMT2AGAA | |
| SCHEMBL22064075 | 0.72 | ALDH1A1 (0.61) | CYP2D6MEN1POLBKMT2ANPSR1 | |
| SCHEMBL10921358 | 0.71 | KMT2A (1.00) | MEN1POLBKMT2ACNR1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060211707-A1 | Piperazine-alkyl-ureido derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-09-21 | — | — | US | disclosed |
| EP-1631565-A1 | PIPERAZINE-ALKYL-UREIDO DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004099179-A1 | PIPERAZINE-ALKYL-UREIDO DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211707-A1 | Piperazine-alkyl-ureido derivatives | ADRA2C, UTS2R, ADRB2 | CYP3A4 1417/4885CYP2D6 1458/4885MEN1 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.